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22 Misdiagnosis of cystic ﬁbrosis in adulthood
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Objectives: Cystic ﬁbrosis (CF) is no longer a disease of childhood. Increased
survival of patients with classic CF and emergence of different clinical forms of
presentation, adults physicians need to attend those forms.
Describe clinical forms that led to the diagnosis in adults, analyze nutritional status,
genetics, pulmonary and pancreatic sufﬁency.
Methods: This study is retrospective, observational and descriptive of 17 adult
patients (4 women and 13 men), with an age range between 18 and 61 years
at diagnosis and 30±9.87 average. From a total of 77 patients seen by an
interdisciplinary team at the Department of Adult Cystic Fibrosis.
The genetic diagnosis was detected 2 mutations in 6 patients. Sweat test was
diagnosed in 11 patients.
Spirometry: FEV1 averaged 62.48±1.37%.
In all patients chest CT showed bilateral bronchiectasis and air trapping.
Bacteriological examination: Pseudomonas aeruginosa (12), methicillin-sensitive
Staphylococcus aureus (8), methicillin-resistant Staphylococcus aureus (6),
Burkholderia cepacia (1).
Pancreatic involvement: 15 were pancreatic sufﬁcient.
Nutritional status assessed by BMI was between 26.4 and 20.8 with an average
of 23.
Previous diagnosis were:
– Bronchitis, pneumonia, asthma and bronchiectasis: 12
– Chronic diarrhea − Bowel obstruction: 9
– Rhinosinusal Disease: 3
– Infertility: 3
– Family screening: 2
Conclusion: CF can be diagnosed at any age and its presentation differ from the
classic appearance, this clinical variability can lead to misdiagnosis if not suspected.
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186−8T/C mutation (c.54−8T/C) in intron 1 of the CFTR gene has never been
reported to our knowledge. It was identiﬁed in a 38 years old Italian woman who
referred to our Center for evaluation because she was treated as CF since 2010
following diagnosis based on repeated sweat tests chloride 60 and 74mEq/L (normal
values <50mEq/L, at the reference clinic) and clinical history consistent with CF;
no mutations were identiﬁed by ﬁrst level genetic analysis; small interstitial-alveolar
inﬁltration were evident in CT scan.
The variant 186−8T/C was identiﬁed by sequencing. Afterwards the patient referred
to our center for assessing the relevance of these ﬁndings. Sweat chloride there was
35 and 57mEq/L. Nasal potential difference (NPD) measurements were therefore
performed with results in the normal range.
We hypothesized that the genetic variant 186−8T/C could affect splicing: the same
fragments as in healthy donor were ampliﬁed by RT-PCR ampliﬁed.
Moreover CFTR function was tested by single cell ﬂuorescence analysis (Sorio
et al. 2011) in leukocytes: tracings were overlapping with healthy donors. This
method is easier for patients and for investigators than currently available and
standardized procedures. Simpliﬁed and feasible functional assays in leukocytes are
under investigation in order to provide an additional tool for investigating genetic
variants of uncertain clinical relevance as well as the effects of drugs targeting the
CF basic defect.
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Background: Signiﬁcant proportion of CF-like patients, who enter CF diagnostic
algorithm end in intermediate categories between CF unlikely, CFTR-related dis-
order and CF. Transheterozygosity for ENaC/CFTR variants may lead to deﬁcient
ENaC/CFTR interaction, abnormal ion transport and CF-like disease, but mecha-
nism of relation between CFTR and ENaC are not well described.
Aim of this study was to evaluate correlation between phenotype, CFTR/ENaC
genotype and channels functionality.
Methods: A total of 51 subjects (53% female, mean age: 16.6, range 6−28 years)
with inconclusive CF diagnosis were investigated by nasal potential difference
(NPD: ENaC-hyperactivity = DPDAmi >17mV; CFTR dysfunction DPD0Cl−+Iso
<−8mV), sweat test, CFTR genotyping (sequencing+MLPA) and sequencing of
coding regions of ENaC genes (SCNN1A, SCNN1B, SCNN1G).
Results: Subjects were classiﬁed as: CF unlikely without ENaC-hyperactivity
(n = 24), CF unlikely with ENaC-hyperactivity (n = 7), CFTR-related disorder
(n = 6), PS-CF (n = 4), PI-CF (n = 4) and ENaC-related disorder independent of
CFTR mutations/dysfunction as a new CF-like clinical entity (n = 6).
Conclusions: This study provides growing evidence of a new “CF-like” diagnostic
category with ENaC-hyperactivity caused by ENaC mutations. CFTR/ENaC func-
tion can be directly measured and separated by NPD, whereas sweat test alone does
not distinguish between ENaC hyperactivity and CFTR dysfunction. ENaC-related
disorder seems to be an underestimated cause of CF-like disease, and reference
values and diagnostic categories are in need of a differentiated update.
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Introduction: CF is characterized by recurrent lung infections, malabsorption,
malnutrition, and male infertility. Some patients with bronquiectasis and without
other clinical features of CF have been associated with mutations in the CFTR gene.
The main objective of this work was to analyze the proﬁle of CFTR mutations in
adult patients diagnosed with idiopathic bronquiectasis.
Patients and Method: Thirty-six Portuguese patients with isolated bronquiectasis
were screened for the 33 most frequent CFTR mutations in the Caucasian population
using the OLA CFTR kit (Abbott) and for the IVS8(TG)mTn variants. In those
patients with only one or no mutations identiﬁed, the CFTR gene sequencing and
MLPA analysis were performed.
Results: Four different mutations were identiﬁed, F508del, R334W, V754M and
IVS8T5. From the 36 patients, 2 (5%) had 2 mutations and 6 (17%) had 1 mutation.
The most frequent mutation detected was the IVS8−5T, detected with an allelic
frequency of 10% and it is associated with the IVS8TG12 repeats in 57% of the
cases.
Conclusions: Eight (22%) patients had at least one CFTR mutation, which is
signiﬁcantly higher than the percentage reported for the general population (4%).
The allelic frequency of the IVS8T5 variant was 10%, also higher than the one
reported for the Caucasian population (5%). The IVS8T5 variant seems to have an
important role in cases of idiopathic bronquiectasis. This is similar to that reported
for CFTR related disorders such as congenital absence of the vas deferens. The
results of this study highlight the importance of CFTR gene screening, including
the analysis of IVS8TGmTn variants in patients with idiophatic bronquiectasis.
